Sentences with phrase «research on biomarkers»
It also calls for «new funding for the National Institutes of Health (NIH) through a temporary «innovation fund,» which would give the agency an extra $ 8.75 billion over 5 years; $ 500 million per year would fund specific projects within NIH's 27 institutes, including research on biomarkers and precision medicine.
http://www.sciencemag.org/ Not exact matches
BiomarkerBase ™ equips busy professionals in research, business development, and marketing roles to easily stay on top of developments in the clinical / commercial use of molecular biomarkers.
Much current research in immuno - oncology focuses on improving these treatments, for example, by finding new immunotherapy targets and identifying biomarkers that predict a patient's response.
The UMD and UMB team, led by research associate Eunkyoung Kim, used a discovery - driven approach based on the assumptions that chemical biomarkers relating to oxidative stress could be found in blood, and that they could be measured by common electrochemical instruments.
«Roadmap for biomarker research on Alzheimer's disease should lead to better results.»
This new study of non-military, civilian trauma patients visiting the emergency department builds on recent research conducted by Dr. Samadani, supported through the Cohen Veterans Center, which found that the use of this novel eye - tracking technology could reveal edema, or swelling, in the brain as a potential biomarker for assessing brain function and monitoring recovery in people with head injuries.
To speed up progress in biomarker - based research, international experts have defined five sequential phases on the road to new diagnosis and therapy options:
Wong's research over the past decade has focused on identifying biomarkers in saliva.
The report, which drew heavily on two Environmental Protection Agency (EPA) workshops held in 1995, also recommends more research on such topics as DNA biomarkers that can gauge an organism's exposure to endocrine disruptors; models for predicting how endocrine disruptors are metabolized; mechanisms of how endocrine disruptors act at a cellular level; and the effects of mixtures.
According to lead author Mr James Oliver of the Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, UK, «in current clinical practice, RA drugs are administered on a trial and error basis; there are no clinical biomarkers of response to guide treatment decisions.
«We extended this biomarker research to the domain of professional sports to test its merit as an objective and rapid way to determine players» severity of brain injury,» says lead author, Robert Siman, PhD, Research Professor of Neurosurgery at Penn. «This blood test may aid neurobiologically - informed decisions on suitability for return to play following a sports - related concussionresearch to the domain of professional sports to test its merit as an objective and rapid way to determine players» severity of brain injury,» says lead author, Robert Siman, PhD, Research Professor of Neurosurgery at Penn. «This blood test may aid neurobiologically - informed decisions on suitability for return to play following a sports - related concussionResearch Professor of Neurosurgery at Penn. «This blood test may aid neurobiologically - informed decisions on suitability for return to play following a sports - related concussion.»
In an article titled, «Allergen Induced Pulmonary Inflammation Enhances Mammary Tumor Growth and Metastasis: Role of CH13L1,» featured on the cover of the current issue of the Journal of Leukocyte Biology, this new research suggests inflammation raises the level of a known biomarker of cancer, called «chitinase -3-like-1» or «CHI3L1,» in the inflamed tissue, which leads to increased metastasis and faster cancer growth in that tissue.
«The findings of both studies support a growing body of research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both studies.
The team's next avenue of research will be focused on identifying a «biomarker» that can identify this distinct suppressive cell elsewhere in the body — for example, in blood or other samples — as a potential predictive clinical tool to determine when these cells are present in patients, which currently can not be done.
This combination of job responsibilities allows her to focus on methods to bridge the gap between research and clinical application of biomarker findings.
His research focuses predominantly on oncology molecular diagnostics, particularly the source and utility of miRNA biomarkers in blood, and the development of innovative molecular diagnostics for the identification of mutations that can guide therapeutic decision - making.
Dr. Quintana's research is focused on the regulation of the adaptive and innate immune response and the identification of biomarkers for multiple sclerosis (MS) and other immune - mediated diseases.
The findings, featured on the cover of the March 7 issue of Cell Reports, show that patients with high levels of the biomarker, CD151, have a poor prognosis, says lead author Mauricio Medrano, a molecular biologist and research associate at Princess Margaret Cancer Centre, University Health Network.
«GECCO aims to continue to discover additional colorectal cancer - related variants by investigating how genetic variants are modified by other environmental and lifestyle risk factors, including biomarkers as well as how they influence patient treatment response and survival,» Peters said, emphasizing how much further research is required to uncover the specific mechanisms by which genes modulate the intake of certain foods on colorectal cancer risk.
In further research, Dr. Evgenii Belykh, the leading research fellow on the project stated, «The imaging findings are being compared with the histology and biomarkers of disk degeneration that will eventually help to recognize and predict the disease earlier, and help to choose the best treatment option for each patient.»
Woolley's research interests in microfluidics focus on using lab - on - a-chip devices to detect biomarkers related to preterm birth.
It is a system for grouping biomarkers and classifying research participants on the basis of biomarker profiles.
«Future research will focus on optimizing the candidate therapies discovered by our team in this study as well as developing biomarkers that can be used to test the efficacy of other potentially promising drugs,» says Dr. Rothstein
To back up those claims, T.A. Sciences plans to submit research demonstrating TA - 65's effects on bone density, immune function, and age - related biomarkers for peer - reviewed publication this year.
Baltimore, Md. (Embargoed until 12:30 pm EDT on Monday, June 8)-- A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
In addition to her expert skill as a clinician, Dr. Frontera also has many research interests including identifying biomarkers and predictors of early brain injury and vasospasm / delayed cerebral ischemia after subarachnoid hemorrhage and their impact on outcome; determining the efficacy of therapeutic strategies and developing guidelines for the management of patients with intracranial hemorrhage; evaluating the cost, length of stay, quality of life, functional and cognitive outcomes in a broader population of intracranial hemorrhage patients; developing guidelines for the integration of palliative care into the intensive care unit setting; and evaluating the relationship of Zika virus infection, Guillain - Barre, and other neurologic disorders.
Research on Alzheimer's Development of highly effective biomarkers for early diagnosis of Alzheimer's disease.
Before he joined Moderna in 2013, Dr. Frederick was a Translational Research group leader at Aveo Oncology, focused on the generation of biomarkers for therapeutic response prediction, as well as avenues to modulate the tumor microenvironment for therapeutic benefit.
The epigenetic changes observed were specific to methoxychlor exposure and may prove to be valuable biomarkers for future research on transgenerational disease.
He completed his postdoctoral training from Columbia University where he later joined as a research scientist to continue his work on identifying master regulators (MR) of various pathologies, developing methods for biomarker discovery and understanding mechanism of action of compounds.
Other areas of research include designing novel therapies based on molecular pathways and identifying predictive biomarkers in patients to design personalized, targeted therapies.
Through regional networks in the U.S. like the Pediatric Neuromuscular Clinical Research (PNCR) Network and Project Cure, and international organizations such as the International Coordinating Committee (ICC) and TREAT - NMD, the SMA community has collaborated effectively on recruiting patients, establishing standards of care, standardizing outcome measures, and supporting multi-site clinical efforts, such as the Biomarkers for SMA (BforSMA) and the PNCR Network Natural History studies.
She was a key collaborator on GVHD biomarker studies conducted within the overarching GVHD research theme of the Michigan BMT Program, including a first - authored paper demonstrating that elevations of CXCL9 are associated with new onset de novo chronic GVHD.
As part of their ongoing research, Ratain and O'Donnell are actively seeking out genetic biomarkers that shed light on how cancer patients will respond to different treatments.
Jeffrey L. Goldberg, MD, PhD (Professor and Chair, Department of Ophthalmology, Stanford University School of Medicine) presented research advances from the Catalyst for a Cure biomarkers team at the Glaucoma 360 New Horizons Forum on February 3, 2017 in San Francisco.
For the last three years the research team has been working on the development of a so - called biomarker to predict treatment effectiveness.
Accelerator Award is a milestone - driven award program ($ 100,000 for 1st year) focused on translational research toward therapeutics or associated biomarkers and diagnostics.
She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T cells as effector cells of the immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.
This workshop focuses on considerations for development of a multiplexed immunoassays; examples of multiplexed assays for research release and other toxicities associated with CAR - T cells; and a novel flexible platform for biomarker screening and assessment of toxicities in samples exposed to CAR - T cells.
PHILADELPHIA --(April 18, 2018)-- An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmarresearch spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmarResearch Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmark study.
Based on progress among the various laboratories and their collaborators, the CFC research team has narrowed their focus on three potential biomarkers.
Research on vaccine biomarkers, including in - depth comparative analysis of data from different platforms, large - scale RNA sequencing, harmonisation of standard operating procedures (SOPs) for sample, microarray and data analysis, as well as transcriptome mapping (more than 1400 samples analysed).
The research focused on the biomarkers involved in the buildup of brain plaques in the caudate and hippocampus.
His recent research has focused on the design and implementation of innovative algorithms to enable proteogenomic data analysis, pattern - based discovery of proteomic biomarker candidates, evaluation of data quality, assessment of variability and reproducibility in mass spectrometry based assays, and data visualization.
The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress.
My research mainly focuses on pathobiology of GI and pancreatic neuroendocrine tumors and identification of diagnostic, prognostic and therapeutic biomarkers for colorectal and pancreatic cancer.
At the annual Association for Research in Vision and Ophthalmology (ARVO) meeting in April, I attended a meeting on «Molecular Biomarkers in Glaucoma» emphasizing the interest in identifying new ways to measure and track glaucoma.
Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters
Miller is widely recognized for his research on the impact of toxins in Parkinson's disease (PD) and has created a unique mouse model of the disease to develop biomarkers of exposure, risk and early disease.
The Metabolomics & Proteomics Technology Unit activity focus on the identification of biomarkers and the functional characterization of metabolic pathways, applied to Research & Development of antimicrobials, vaccines, diagnostic tests or probiotics.